Bicara Therapeutics Inc.

Contributing Author

Recent Articles by Bicara Therapeutics Inc.

Apr-03	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
Mar-30	Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Mar-23	Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET BCAX GlobeNewswire
Mar-04	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
Feb-26	Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares BCAX GlobeNewswire
Feb-24	Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants BCAX +7.82% GlobeNewswire
Feb-24	Bicara Therapeutics Announces Proposed Public Offering of Common Stock BCAX +7.82% BCAX GlobeNewswire
Feb-23	Bicara Therapeutics to Participate in Upcoming Investor Conferences BCAX +5.94% GlobeNewswire
Feb-19	Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen BCAX +6.42% GlobeNewswire
Feb-05	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BCAX -7.76% GlobeNewswire
Jan-12	Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook BCAX GlobeNewswire
Dec-15	Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 BCAX GlobeNewswire
Dec-06	Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 BCAX GlobeNewswire
Dec-01	Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 BCAX -6.63% GlobeNewswire
Nov-10	Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Oct-13	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC BCAX GlobeNewswire
Aug-27	Bicara Therapeutics to Participate in Upcoming Investor Conferences BCAX GlobeNewswire
Aug-12	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Jun-03	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference BCAX +11.21% GlobeNewswire
Jun-01	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 BCAX GlobeNewswire
May-22	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting BCAX -40.80% BCAX +7.33% GlobeNewswire
May-13	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update BCAX -8.10% GlobeNewswire

Bicara Therapeutics Inc.

Recent Articles by Bicara Therapeutics Inc.

Upgrade your Finviz experience